EXTAVIA Drug Profile

Summary for Tradename: EXTAVIA

High Confidence Patents:	1
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for EXTAVIA

Recent Clinical Trials for EXTAVIA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Biogen	Phase 4
MediciNova	Phase 2
National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2

See all EXTAVIA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EXTAVIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EXTAVIA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	7,588,755	2026-09-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for EXTAVIA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	10,085,955	2034-01-08	Patent claims search
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	10,233,171	2037-02-24	Patent claims search
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	10,265,291	2037-02-13	Patent claims search
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	10,273,252	2036-06-14	Patent claims search
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	10,350,178	2038-08-23	Patent claims search
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	10,428,382	2033-03-07	Patent claims search
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	10,493,080	2037-01-27	Patent claims search

International Patents for EXTAVIA

Country	Patent Number	Estimated Expiration
Japan	3158952
Croatia	P921091
Japan	H10304876
Poland	231111
South Korea	860001471
Hungary	193507
Netherlands	970018

Supplementary Protection Certificates for EXTAVIA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
96C0019	Belgium		PRODUCT NAME: BETAFERON INTERFERON BETA-1B; REGISTRATION NO/DATE: EU/1/95/003/001 19951130
SZ 10/1996	Austria		PRODUCT NAME: BETAFERON - INTERFERON BETA-1B

Market Dynamics and Financial Trajectory for Extavia

Last updated: February 19, 2026

What is Extavia?

Extavia (interferon beta-1b) is a biologic drug indicated for multiple sclerosis (MS), branded by Novartis. It is a variant of interferon beta-1b, a protein that modulates the immune response to reduce MS relapse frequency and disease progression.

Market Size and Growth Drivers

Global Multiple Sclerosis Market

• Valued at approximately $23.8 billion in 2022.
• Expected compound annual growth rate (CAGR) of 4.2% from 2023 to 2030.
• Driven by rising prevalence, expanding treatment indications, and innovation in biologic therapies.

Extavia's Position

• Estimated to hold a 2-3% share within the MS biologics segment.
• Market presence limited compared to rivals such as Avonex (Biogen), Rebif (Eli Lilly), and Tecfidera (Bayer).

Key Growth Factors

• Increasing MS diagnosis rates, approximately 2.8 million globally, with a rising incidence in developing markets.
• Growing approval and adoption of biosimilars, although biosimilars for interferon beta-1b are limited.
• Expanded authorized indications, including in pediatric MS and early disease intervention.

Competitive Landscape

Drug Name	Manufacturer	Market Share (2022)	Pricing (USD/year)	Administration	Approval Date
Avonex	Biogen	35%	60,000	Weekly IM	1996
Rebif	EMD Serono	20%	65,000	Three times/week SC	1996
Extavia	Novartis	3%	62,000	Every other day SC	2009
Tecfidera	Biogen	10%	65,000	Oral daily	2013

The limited market share and high compliance barriers for injectable biologics shape Extavia's competitive positioning.

Revenue Trajectory

Past Performance (2020-2022)

• Estimated revenue: $150-$250 million annually.
• Flat to declining due to market saturation and generic competition for other interferons.

Forecast (2023-2030)

• Modest growth projected, driven by increased MS diagnosis rates.
• Potential sales increase of 1-3% annually if new indications or formulations are approved.
• Introduction of biosimilars may pressure prices and margins.

Pricing and Reimbursement Policies

• Prices are region-dependent; notable discounts in Europe and emerging markets.
• Reimbursement policies favor oral and high-efficacy therapies, reducing injectable biologics' revenue.

Regulatory and Patent Landscape

• Patent expiry for some interferon formulations expected around 2025-2026.
• Limited biosimilar competition yet; future entries could impact revenue.
• Recent approvals in emerging markets bolster market presence, though revenue impact remains limited.

Financial Outlook

Year	Projected Revenue (USD millions)	Assumptions
2023	150 - 200	Stable market with no significant biosimilar competition
2025	140 - 180	Beginning biosimilar entries, price competition
2027	130 - 170	Increased generic competition, price erosion
2030	120 - 160	Market saturation, biosimilar proliferation

Risks and Opportunities

Risks

• Biosimilar entries reducing prices.
• Regulatory delays impacting new indications.
• Increased competition from oral MS therapies like Gilenya and Tecfidera.
• Trade tariffs affecting global pricing.

Opportunities

• Expanding indications, especially in pediatric MS.
• Developing high-concentration formulations to improve compliance.
• Strategic partnerships in emerging markets.

Key Takeaways

• Extavia maintains niche positioning within the MS biologics market.
• Revenue remains static with slight decline prospects due to biosimilar pressure.
• Market growth depends on expanding indications and regional penetration.
• Patent expiries and biosimilar competition forecast disruptive impacts after 2025.
• Pricing and reimbursement policies significantly affect revenue potential.

FAQs

Q1: Will biosimilars significantly decrease Extavia’s revenues?
A1: Yes; biosimilar entrants could erode market share and lower prices after patent expirations around 2025–2026.

Q2: Are there new indications that could expand Extavia’s market?
A2: Potential exists for pediatric MS and early intervention approval, which may broaden use cases.

Q3: How does Extavia compare financially with other interferon beta drugs?
A3: It is priced similarly but has a smaller market share, limiting revenue impact despite comparable costs.

Q4: What regional factors affect Extavia’s sales?
A4: Reimbursement policies and healthcare infrastructure in Europe, Asia-Pacific, and emerging markets influence adoption rates.

Q5: What is the outlook for Extavia’s long-term viability?
A5: Challenged by biosimilar competition and evolving treatment standards; success depends on formulary positioning and indication expansion.

---

References

1. MarketsandMarkets. (2022). Multiple sclerosis therapeutics market size. https://www.marketsandmarkets.com/Market-Reports/multiple-sclerosis-therapeutics-market-622.html
2. Novartis. (2023). Extavia product information. https://www.novartis.com/
3. EvaluatePharma. (2023). 2022 Pharmaceutical sales data. https://www.evaluate.com/
4. FDA. (2020). Patent expiry dates for biologics. https://www.fda.gov/
5. IQVIA. (2023). Global healthcare market report. https://www.iqvia.com